Zentalis Pharmaceuticals, Inc.ZNTLNASDAQ
Loading
R&D Expenses Over TimeContracting
Percentile Rank43
3Y CAGR-13.8%
5Y CAGR+5.5%
Year-over-Year Change
Research and development spending
3Y CAGR
-13.8%/yr
vs +73.8%/yr prior
5Y CAGR
+5.5%/yr
Recent deceleration
Acceleration
-87.6pp
Decelerating
Percentile
P43
Within normal range
vs 5Y Ago
1.3x
Solid growth
Streak
2 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| TTM | $110.78M | -34.0% |
| 2024 | $167.77M | -28.7% |
| 2023 | $235.16M | +36.1% |
| 2022 | $172.73M | -1.6% |
| 2021 | $175.60M | +106.8% |
| 2020 | $84.90M | +121.2% |
| 2019 | $38.39M | +102.9% |
| 2018 | $18.92M | - |